Finasteride is one of the most studied treatments for androgenetic alopecia (male pattern hair loss). It works by inhibiting the 5-alpha reductase enzyme, reducing conversion of testosterone to DHT. For hair loss, the standard dose is 1 mg orally once daily, and evidence suggests 1 mg is not meaningfully less effective than 5 mg for scalp outcomes.

Want help deciding whether finasteride is appropriate for your specific pattern and risk profile?
Browse verified trichologists near you.

Quick next steps (so you’re not guessing)

How finasteride works

Finasteride is a selective 5-alpha reductase inhibitor. For androgenetic alopecia, it is typically prescribed as 1 mg orally once daily. Oral bioavailability averages around 65% and is not meaningfully affected by food intake. Finasteride is metabolized in the liver (CYP3A4 pathways) and eliminated in urine and feces.

Clinical dose-ranging research has explored doses from 0.2 mg to 5 mg. For men with androgenetic alopecia, 1 mg daily is the best-supported dose, and evidence does not show a major difference in efficacy between 1 mg and 5 mg for scalp outcomes.

Methods

A literature review was conducted for evidence on finasteride use in male pattern baldness and female pattern hair loss using major databases (MEDLINE, EMBASE, CINAHL, LILACS, and Cochrane registers), covering publications up to March 2014. Study types reviewed included systematic reviews, meta-analyses, national guidelines, randomized controlled trials, prospective open-label studies, and retrospective case series (English-language).

How evidence was graded

  • Grade A: High-quality evidence directly applicable, consistent results, strong confidence.
  • Grade B: Good evidence, generally consistent, but not as strong as Grade A.
  • Grade C: Moderate evidence, some limitations, but still informative.
  • Grade D: Weak evidence or expert opinion due to limited data.

Results

A total of 262 studies were identified, and 12 met inclusion criteria for the review.

Does finasteride work for androgenetic alopecia (male pattern hair loss)?

  • A systematic review of 12 studies suggests oral finasteride improves hair count and appearance assessed by patients and investigators (evidence level 1+).
  • Long-term use (up to 5 years) may reduce likelihood of further visible hair loss (evidence level 1+).
  • Some evidence suggests earlier initiation may improve response (evidence level 1+).
  • A 10-year follow-up study reported sustained effectiveness over time, including delayed responders (evidence level 1++).
  • Combination regimens (finasteride with minoxidil and/or ketoconazole) showed improved outcomes vs minoxidil-only in some studies (evidence level 1+).
  • A study comparing 3% minoxidil vs 3% minoxidil + 0.1% finasteride showed better results with the combination (evidence level 1+).
  • One study suggested topical finasteride gel (1% twice daily) may be close to oral finasteride in efficacy, but evidence remains limited (evidence level 1+).

Bottom line: For men with androgenetic alopecia, 1 mg oral finasteride daily is supported as an effective treatment, especially when started earlier. Combination with minoxidil is promising (grade B). Topical finasteride evidence is still limited and needs more research (grade B).

Side effects

The most discussed concern with finasteride is sexual side effects, which can affect adherence. Evidence is mixed: many controlled studies report low rates near placebo, while some observational and survey-based studies report a subset of individuals with significant or persistent symptoms.

Studies that report side effects as not significant

Several studies report sexual adverse effects in the range of 2.1% to 3.8%, comparable to placebo. Reported effects include erectile dysfunction, ejaculatory dysfunction, and decreased libido. These effects are often described as occurring early and resolving either after discontinuation or sometimes with continued use. Some authors discuss a possible nocebo effect contributing to symptom reporting.

Studies that report significant or persistent side effects

Some studies suggest a subset of individuals may experience significant and potentially persistent sexual side effects. These studies have limitations including small sample sizes, selection bias, recall bias, and inconsistent hormone testing (grade C).

Finasteride and prostate cancer

In a large prostate cancer prevention trial using finasteride 5 mg, finasteride reduced overall prostate cancer incidence but was associated with increased detection of high-grade disease (evidence level 1+). Long-term follow-up did not show significant differences in overall survival or survival after prostate cancer diagnosis (evidence level 1+). Data specifically linking prostate cancer risk to the 1 mg dose are limited (grade B).

Positions from professional bodies and regulators

International Society of Hair Restoration Surgery (ISHRS)

A dedicated task force reviewed published data and did not find substantial evidence of sexual dysfunction linked to once-daily 1 mg finasteride for hair loss, while emphasizing cautious interpretation of anecdotal reports and the need for more research.

FDA stance and labeling updates

The FDA reviewed post-marketing reports related to sexual dysfunction for 1 mg finasteride (1998–2011) and noted many reports described normalization within three months of discontinuation. In controlled trials, 3.8% of finasteride users reported one or more sexual adverse events versus 2.1% with placebo.

On April 11, 2012, the FDA updated labels for Propecia (1 mg) and Proscar (5 mg) to include reports of libido disorders, ejaculation disorders, and orgasm disorders that persisted after discontinuation, and to note reports of male infertility and/or poor semen quality that generally improved after stopping.

IADVL Therapeutic Guidelines Committee summary

  1. Effectiveness: Finasteride is effective for androgenetic alopecia.
  2. Mechanism and efficacy: Well-established.
  3. Safety: Many studies support long-term safety; no definitive causal link established for persistent sexual side effects.
  4. Alternatives: No clearly safer, proven alternative with similar efficacy identified.
  5. Patient counseling: Clear counseling on benefits and risks is required.
  6. Reporting side effects: Patients should report side effects promptly.
  7. Voluntary use: Treatment is elective; hair loss may progress without it.
  8. Informed decision-making: Clinicians should provide sufficient information for informed consent.
  9. Fertility considerations: Avoid prescribing in men with known oligospermia/infertility especially when family planning is imminent; consider alternatives for highly apprehensive patients. No semen analysis is required before prescribing.
  10. No coercion: Do not pressure patients.
  11. Staggered dosing (expert opinion): Lower or staggered dosing may be considered for anxious patients, but this is expert opinion (grade D).

Finasteride for female pattern hair loss

Evidence is mixed and limited. A placebo-controlled study in postmenopausal women using 1 mg daily did not show meaningful benefit vs placebo after one year. Some small studies suggest higher doses (2.5–5 mg daily) may be beneficial in certain postmenopausal, normoandrogenic populations, but evidence quality is limited (grade C).

  • Finasteride is not recommended for women of childbearing potential unless strict contraception is in place due to teratogenic risk.
  • Expect slow timelines: stabilization can take ~12 months; any regrowth may take 24 months or longer.

Summary

Finasteride remains a well-supported option for male androgenetic alopecia at 1 mg daily, with evidence for sustained benefit over years and potential synergy with minoxidil. The trade-off is the ongoing debate about sexual side effects, including the question of persistence in a subset of users. Regardless of stance, the practical takeaway is simple: patients should be properly counseled, risks and benefits should be weighed honestly, and the decision should remain voluntary and informed.

References

1. Stough D, Stenn K, Haber R, Parsley WM, Vogel JE, Whiting DA, et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin Proc 2005;80:1316-22.
[Google Scholar]
2. Sawaya ME. Antiandrogens and androgen inhibitors. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia: Saunders; 2007. p. 417-35.
[Google Scholar]
3. Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, Shupack J, et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 1999;41:555-63.
[Google Scholar]
4. Rossi A, Cantisani C, Scarnò M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther 2011;24:455-61.
[Google Scholar]
5. Kaufman KD, Girman CJ, Round EM, Johnson-Levonas AO, Shah AK, Rotonda J. Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): Long-term (5-year) controlled observational data in placebo-treated patients. Eur J Dermatol 2008;18:407-11.
[Google Scholar]
6. Kaufman KD, Rotonda J, Shah AK, Meehan AG. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol 2008;18:400-6.
[Google Scholar]
7. Bell HK, Ormerod AD. BAD Therapy and Guidelines Subcommittee. Writing a British Association of Dermatologists clinical guideline: An update on the process and guidance for authors. Br J Dermatol 2009;160:725-8.
[Google Scholar]
8. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: A systematic review. Arch Dermatol 2010;146:1141-50.
[Google Scholar]
9. Camacho FM, García-Hernández MJ, Fernández-Crehuet JL. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: Better response in patients under 26 years old. Br J Dermatol 2008;158:1121-4.
[Google Scholar]
10. Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol 2002;29:489-98.
[Google Scholar]
11. Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: A randomized, double-blind, comparative study. J Med Assoc Thai 2012;95:1312-6.
[Google Scholar]
12. Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol 2009;75:47-51.
[Google Scholar]
13. Chandrashekar BS, Nandhini T, Vasanth V, Sriram R, Navale S. Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J 2015;6:17-20.
[Google Scholar]
14. Cecchin E, De Mattia E, Mazzon G, Cauci S, Trombetta C, Toffoli G. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. Int J Biol Markers 2014;29:e310-6.
[Google Scholar]
15. Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-finasteride: A survey of men reporting symptoms. Am J Mens Health 2015;9:222-8.
[Google Scholar]
16. Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: The connection. J Sex Med 2008;5:2917-24.
[Google Scholar]
17. Carbone DJ Jr, Hodges S. Medical therapy for benign prostatic hyperplasia: Sexual dysfunction and impact on quality of life. Int J Impot Res 2003;15:299-306.
[Google Scholar]
18. Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al. Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon? J Sex Med 2007;4:1708-12.
[Google Scholar]
19. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1999;41:555-63.
[Google Scholar]
20. Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999;40(6 Pt 1):930-7.
[Google Scholar]
21. Moinpour CM, Darke AK, Donaldson GW, Thompson IM Jr, Langley C, Ankerst DP, et al. Longitudinal analysis of sexual function reported by men in the prostate cancer prevention trial. J Natl Cancer Inst 2007;99:1025-35.
[Google Scholar]
22. Sonthalia S, Sahaya K, Arora R, Singal A, Srivastava A, Wadhawan R, Zartab H, Gupta KS. Nocebo effect in dermatology. Indian J Dermatol Venereol Leprol 2015;81:242-50.
[Google Scholar]
23. Anitha B, Inamadar AC, Ragunatha S. Finasteride-its impact on sexual function and prostate cancer. J Cutan Aesthet Surg 2009;2:12-6.
[Google Scholar]
24. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med 2011;8:1747-53.
[Google Scholar]
25. Collodel G, Scapigliati G, Moretti E. Spermatozoa and chronic treatment with finasteride: A TEM and FISH study. Arch Androl 2007;53:229-33.
[Google Scholar]
26. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: Persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011;8:872-84.
[Google Scholar]
27. Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf 2013;12:81-90.
[Google Scholar]
28. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
[Google Scholar]
29. Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 2013;369:603-10.
[Google Scholar]
30. Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 1999;41:550-4.
[Google Scholar]
31. Rajput RJ. Cyclical medicine for hair loss management and improved results in hair transplantation. Hair Transplant Forum Int 2008;18:208-10.
[Google Scholar]
32. Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother 2010;44:1090-7.
[Google Scholar]
33. Price VH, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000;43(5 Pt 1):768-76.
[Google Scholar]
34. Yeon JH, Jung JY, Choi JW, Kim BJ, Youn SW, Park KC, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol 2011;25:211-4.
[Google Scholar]
35. Trüeb RM; Swiss Trichology Study Group. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004;209:202-7.
[Google Scholar]